Table 5. Data on children and adolescents with giant cell tumor of bone treated with denosumab reported in the literature.

Study	Year	Patient age	Dose and interval of denosumab	Duration of treatment	Effect of treatment	Adverse events during treatment	Adverse events after treatment
Chawla et al. (27)	2013	10 children ≥12 years old	120 mg monthly	Ongoing	Decreased tumor size, improved pain	None	Unknown
Karras et al. (28)	2013	10-year-old girl	120 mg monthly	24 months	Decreased tumor size, improved pain	Mild hypocalcemia and hypophosphatemia	Severe hypercalcemia
Gossai et al. (29)	2015	10-year-old girl	120 mg monthly	24 months	Decreased tumor size, improved pain	Mild hypocalcemia and hypophosphatemia	Severe hypercalcemia
Setsu et al. (30)	2016	10-year-old boy	120 mg monthly	14 months	Decreased tumor size, improved pain	None	Severe hypercalcemia
Kobayashi et al. (31)	2015	10-year-old boy	120 mg monthly	14 months	Decreased tumor size, improved pain	None	Severe hypercalcemia
Uday et al. (9)	2018	14-year-old girl and 15-year-old boy	120 mg subcutaneously on days 1, 8, 15, and 28, and then every 4 weeks	1.3 years	Unknown	Unknown	Osteonecrosis of the jaw rebounded hypercalcemia, acute kidney injury
Sydlik et al. (32)	2020	6–17 years old	60 mg on days 1, 8, 15, and 28 and then once a month	7–17 months	Decreased tumor size	Unknown	Tumor relapse, hypercalcemia
Reddy et al. (33)	2021	14-year-old and 16-year-old	120 mg subcutaneously once weekly for 3 weeks during the first cycle then once every 4 weeks with plans to complete a total of 26 cycles	14/26 (26 months)	Reduction in tumor size	Mild hypocalcemia	None